FDA
-
-
-
-
-
-
-
NeOnc Charting New Nasal Route to Treating Brain Cancer
-
-
-
-
-
-
-
Insiders Continue Buying, as NeOnc Moves NEO100 Toward Its Next Regulatory Test
-
-
-
-
-
-
-
NeOnc Technologies Holdings, Inc. Announces Pricing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules with New and Existing Institutional Investors
-
-
-
-
-
-
-
NTHI’s Nasdaq Advantage Takes on New Meaning After Its Breakthrough Phase 2a Results
-
-
-
-
-
-
-
NeOnc's NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5x
-
-
-
-
-
-
-
NeOnc posts wider Q2 loss, plans NEO100 trial data release Aug. 12
-
-
-
-
-
-
-
Three Biotechs Deliver Catalysts to Watch
-
331,932 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

